T he use of organic nitrates has demonstrated great promise in the treatment of both acute and chronic congestive heart failure (CHF). The drugs have been reported to exert a favorable hemodynamic effect,' to enhance exercise capacity,2 and in combination with the arterial dilator hydralazine, possibly to improve survival in patients with mild to moderate CHF.3 Recent information, however, has suggested that the efficacy of nitrate therapy may be severely limited by early development of tolerance leading to a marked attenuation of its initial hemodynamic effect.4 Several investigations have demonstrated rapid development of tolerance to nitrate when administered continuously either intravenously5-7 or topically.8-'1 This phenomenon seems to be preventable by intermittent therapy with periodic discontinuation of drug administration to allow relatively long nitrate washout periods.611 Oral isosorbide dinitrate (ISDN) is the nitrate preparation most widely used in the treatment of chronic CHF. There is, however, no information available regarding the developihent of tolerance with this form of therapy in patients with CHF and the optimal regimen required to prevent its occurrence. Therefore, the purpose of the present study was to evaluate the effects of various dosing regimens of oral ISDN on the development of tolerance to its initial hemodynamic effect in an attempt to form a rational basis to the dosing intervals of this drug in the treatment of patients with CHF.
Methods

Study Patients
Seventy-one patients with chronic CHF due to left ventricular (LV) systolic dysfunction who were admitted with worsening symptoms entered the study. Twenty-seven patients were excluded from the study or data analysis for the following reasons: lack of hemodynamic response (17 patients), increasing symptoms during baseline (three patients) or during the study (one patient), incomplete or technically inadequate data (four patients), development of psychosis (one patient), or transient ischemic attack (one patient) during the study. Forty-four patients responded to ISDN therapy and completed the study. There were 32 men and 12 women ranging in age from 23 to 83 years (mean+SD, 53±13 years).
The cause of CHF was suspected to be coronary artery disease in seven patients and dilated cardiomyopathy in 37 patients. Of the patients with dilated cardiomyopathy, a past history of hypertension was obtained in 12 patients, of excessive alcohol consumption in 12 patients, of both in four patients, and of peripartum cardiomyopathy in one patient. No patient had primary valvular disease or clinical evidence of active myocardial ischemia at the time of the study. All patients were classified on admission in the New York Heart Association functional classes III or IV but were in stable clinical and hemodynamic condition at the time of the study. The diagnosis of LV systolic dysfunction was confirmed by contrast or radionuclide ventriculography in 35 patients and demonstrated LV ejection fraction ranging from 8% to 39% (mean, 22+7%). In the remaining nine patients, LV systolic dysfunction was confirmed by echocardiography.
Hemodynamic Measurements and Computations
Right heart catheterization was performed with a balloon-tipped, triple-lumen Swan-Ganz catheter. Pressures in the right atrium and pulmonary artery and LV filling pressure, determined indirectly from the mean pulmonary artery wedge pressure (PAWP), were recorded on Electronics for Medicine VR-12 or AR-6 recorders; mean pressures were obtained by electronic integration. Heart rate was determined from the electrocardiographic recording, and arterial blood pressure was measured by the standard cuff method. Cardiac output was determined by thermodilution as previously described. 13 Calculations of mean arterial blood pressure, cardiac index, stroke volume index, systemic vascular resistance, and pulmonary vascular resistance were performed by standard formulas.14 Serum levels of ISDN were determined by gas-liquid chromatography.15
Study Protocol
After the patients were clinically stabilized, right heart catheterization was performed at least 16 hours before the onset of the study to guard against previously reported spontaneous hemodynamic changes after the procedure.'6 All forms of organic nitrates and other long-acting vasodilators were withheld for at least 24 hours. Prestudy doses of digitalis and diuretic therapy were continued throughout the study period. On the day of the study, baseline hemodynamic measurements were taken every 30 minutes to achieve two consecutive measurements with less than 10% variation. The values determined at the last measurement were used as baseline data. All patients were then given 40 mg of oral ISDN, and repeat hemodynamic measurements were obtained hourly for 4 hours. Hemodynamic response to ISDN was defined as a 20% or greater decrease in PAWP sustained for 1 hour or more (two consecutive measurements). The definition of response was based on a previously reported5 coefficient of variation of 17% in serial measurements over 24 hours in a group of patients with chronic CHF and similar hemodynamic profile treated with placebo. In responders to 40 mg ISDN, hemodynamic measurements were repeated every 1-2 hours for 30 hours. In nonresponders to this dose, a washout period of 24 hours or longer was allowed, and 120 mg ISDN was then administered following an identical protocol. Nonresponders to CHF3 and by recent preliminary data32 demonstrating added hemodynamic efficacy of ISDN in patients with chronic CHF already treated with angiotensin-converting enzyme inhibitors. Such a combination therapy may enhance hemodynamic effect during a period of anticipated maximum symptoms and help to maintain a more favorable hemodynamic profile during long nitrate interdose intervals or washout periods.
Substantial hemodynamic fluctuations with oral ISDN given Q 8 hours may be preventable with the use of longer-acting nitrate preparation. Such an assumption is supported by previous studies demonstrating persistent hemodynamic effect lasting for at least [10] [11] [12] hours with the use of transdermal nitroglycerin11 and a recent report by Sharpe et a112 demonstrating long-term efficacy of transdermal nitroglycerin given intermittently allowing a daily 8-hour "nitrate-free" interval.
Summary
The present study compared in a prospective, randomized fashion the persistence of hemodynamic response to oral ISDN as manifested by its effect on LV filling pressure in four groups of responders (11 patients in each group) with moderate to severe chronic CHF randomized to receive the drug Q 4 hours, Q 6 hours, Q 8 hours, or t.i.d. (at 0, 6, 12, and 24 hours). The outcome of this study indicates early development of tolerance to the initial effect on LV filling pressure with frequent dosing (Q 4 hours and Q 6 hours, which may be related to persistently elevated ISDN trough plasma levels. Tolerance was reversed with complete restoration of hemodynamic effect after a washout period of 12 hours. ISDN Q 8 hours seemed to prevent early development of tolerance; however, this regimen resulted in only intermittent hemodynamic effect with significant reduction in LV filling pressure for only 12 hours or less of the 30-hour study duration. These results demonstrate the difficulty of achieving a continuous reduction in LV filling pressure with oral ISDN either because of early development of tolerance seen with frequent administration or because of inconsistent effect as a result of long interdose intervals. Further evaluation is needed before the implications of these findings on long-term efficacy of the drug can be fully understood. However, the results of this study point out the limitation of continuous administration of frequent dosing of oral ISDN and suggest the need for intermittent therapy allowing a daily nitrate washout interval and the rationale for combined vasodilator therapy in patients with CHF in order to prevent hemodynamic worsening during long nitratewashout or interdose intervals.
